Based on the presented results of various studies, the prospect of ovarian cancer therapy appears promising by directly targeting cancer stem cells (CSCs), which significantly contribute to drug-resistant tumour relapse, using an anti-CD133-targeted toxin. Here, PROM1 is linked to neoplasm.